The European Union said this week about the data from GSK and Novartis that the adjuvanted ones were too limited to warrant recommending a single dose schedule, but added that one dose might be sufficient in adults. How are we going to track that? How are we going to find out if people really are protected after one dose? When will that decision get made? And will you then have to remount a campaign for those for whom a second dose is being recommended?
On October 26th, 2009. See this statement in context.